WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Promising candidates, such as NDI-219216, GSK4418959, HRO761, and RO7589831, are in the early stages of clinical development, underscoring both scientific credibility and market opportunity. These therapies are designed to exploit synthetic lethality in MSI-high tumors, offering a precision therapy option for cancers with limited existing treatment options. LAS VEGAS Nov. 12, 2025 /PRNewswire/ -- DelveInsight's WRN Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Colorectal Cancer, Endometrial Cancer, and Solid Tumors. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging WRN inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into leading markets (the U
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance [Yahoo! Finance]Yahoo! Finance
- IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND ClearanceBusiness Wire
- IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND ClearanceBusiness Wire
- IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor TypesPR Newswire
- A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds [Yahoo! Finance]Yahoo! Finance
IDYA
Earnings
- 11/4/25 - Beat
IDYA
Sec Filings
- 12/5/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- IDYA's page on the SEC website